Alliancebernstein L.P. Insmed Inc Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Insmed Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 2,450,093 shares of INSM stock, worth $162 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

2,450,093

Previous 2,492,275 1.69%

Holding current value

$162 Million

Previous $167 Million 7.11%

% of portfolio

0.06%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $2.62 Million - $3.33 Million	-42,182 Reduced 1.69%	2,450,093 $179 Million
Q2 2024 Aug 14, 2024	BUY	$22.0 - $69.71 $7.61 Million - $24.1 Million	345,796 Added 16.11%	2,492,275 $167 Million
Q1 2024 May 14, 2024	SELL	$25.72 - $29.94 $36,599 - $42,604	-1,423 Reduced 0.07%	2,146,479 $58.2 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $3.44 Million - $4.66 Million	-146,894 Reduced 6.4%	2,147,902 $66.6 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $4.56 Million - $6.19 Million	-229,847 Reduced 9.1%	2,294,796 $57.9 Million
Q2 2023 Aug 15, 2023	BUY	$16.44 - $21.1 $826,192 - $1.06 Million	50,255 Added 2.03%	2,524,643 $53.3 Million
Q1 2023 May 15, 2023	SELL	$16.26 - $21.73 $2.11 Million - $2.82 Million	-129,796 Reduced 4.98%	2,474,388 $42.2 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $1.62 Million - $2.21 Million	95,622 Added 3.81%	2,604,184 $52 Million
Q3 2022 Nov 15, 2022	SELL	$20.88 - $28.21 $6.3 Million - $8.51 Million	-301,662 Reduced 10.73%	2,508,562 $54 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $2.37 Million - $3.57 Million	-138,825 Reduced 4.71%	2,810,224 $55.4 Million
Q1 2022 May 13, 2022	BUY	$20.42 - $28.13 $2.66 Million - $3.66 Million	130,036 Added 4.61%	2,949,049 $69.3 Million
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $15.6 Million - $20.2 Million	603,211 Added 27.22%	2,819,013 $76.8 Million
Q3 2021 Nov 10, 2021	BUY	$22.46 - $29.47 $3.81 Million - $4.99 Million	169,447 Added 8.28%	2,215,802 $61 Million
Q2 2021 Jul 30, 2021	BUY	$24.17 - $36.01 $5.47 Million - $8.14 Million	226,113 Added 12.42%	2,046,355 $58.2 Million
Q1 2021 May 06, 2021	SELL	$32.28 - $44.3 $408,148 - $560,129	-12,644 Reduced 0.69%	1,820,242 $62 Million
Q4 2020 Feb 08, 2021	SELL	$31.45 - $40.54 $8.44 Million - $10.9 Million	-268,375 Reduced 12.77%	1,832,886 $61 Million
Q3 2020 Nov 12, 2020	BUY	$26.0 - $34.5 $10.6 Million - $14.1 Million	408,227 Added 24.11%	2,101,261 $67.5 Million
Q2 2020 Aug 13, 2020	BUY	$14.11 - $29.42 $22.1 Million - $46.2 Million	1,569,134 Added 1266.45%	1,693,034 $46.6 Million
Q1 2020 May 14, 2020	BUY	$13.63 - $33.98 $70,876 - $176,695	5,200 Added 4.38%	123,900 $1.99 Million
Q4 2019 Feb 18, 2020	BUY	$16.12 - $24.98 $190,216 - $294,764	11,800 Added 11.04%	118,700 $2.84 Million
Q3 2019 Nov 14, 2019	SELL	$15.49 - $25.78 $1.13 Million - $1.88 Million	-72,954 Reduced 40.56%	106,900 $1.89 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $1.01 Million - $1.41 Million	43,702 Added 32.1%	179,854 $4.6 Million
Q1 2019 May 14, 2019	BUY	$13.91 - $31.15 $330,390 - $739,874	23,752 Added 21.13%	136,152 $3.96 Million
Q4 2018 Feb 13, 2019	SELL	$11.6 - $18.7 $18,560 - $29,920	-1,600 Reduced 1.4%	112,400 $1.48 Million
Q2 2018 Aug 13, 2018	SELL	$20.0 - $29.72 $1.36 Million - $2.02 Million	-67,800 Reduced 37.29%	114,000 $2.7 Million
Q1 2018 May 14, 2018	BUY	$21.69 - $32.99 $629,010 - $956,710	29,000 Added 18.98%	181,800 $4.09 Million
Q4 2017 Feb 13, 2018	BUY	$26.43 - $31.78 $470,454 - $565,684	17,800 Added 13.19%	152,800 $4.76 Million
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $1.57 Million - $4.21 Million	135,000	135,000 $4.21 Million

Others Institutions Holding INSM

# of Institutions

465

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $8.98B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Insmed Inc Transaction History